GlassScriptPhysician profile
Erik Barba
NPI 1396492609
$12,377.66
in general payments reported to CMS, 2019-2025
23 companies · $4,431 in 2025
The $4,431 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,218 · 2023: $3,361 · 2024: $3,368 · 2025: $4,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $17.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,142.66 |
| Education | $17.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,954.65 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,507.68 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,351.84 | 2022-2025 | Caplyta |
| Corium, LLC | $1,155.42 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $1,137.41 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $990.18 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $725.58 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $695.79 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $490.95 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $484.98 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| E.R. Squibb & Sons, L.L.C. | $470.61 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $360.52 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $286.22 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $202.72 | 2022-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $179.12 | 2022-2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $166.86 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $65.71 | 2024-2025 | Xelstrym |
| Neos Therapeutics, LP | $39.43 | 2022-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $33.32 | 2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $20.32 | 2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $20.11 | 2022 | |
| Vertical Pharmaceuticals, LLC | $20.02 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $18.22 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Barba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.